Celgene’s pipeline has delivered another new drug filing for Bristol-Myers Squibb, thanks to positive results for oral azacitidine formulation CC-486 in the phase 3 QUAZAR AML-001 trial. Top-line ...
24.4 46.6 (22.2) - CH / 800 m / tf / 6 bt 6 / T C Guta / Swimming ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results